Questions are answered by experts at the Oregon Health Authority, other state agencies or community partners. Questions and ...

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes causing invasive disease. [134] In the face of these changes ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

The First in China! BLA Submitted for Luzhu Biotech's Recombinant Herpes Zoster Vaccine Expected to Be Launched in 2026 HONG KONG ...

Prevenar 13 is a vaccine, which is a type of medicine ... Prevenar 13 is a mixture of the outer sugar coating (polysaccharide) from 13 different strains or serotypes of bacteria called ...

followed 1 month later with 23-valent polysaccharide vaccine (PPSV23). The immune responses to Prevnar 20 in patients aged 18 to 59 years were also assessed, along with the safety profile of ...

This made it possible to produce a very complex, but practical, 23-valent polysaccharide vaccine against the disease 9,10. This approach reached its limits when conjugate vaccines were developed.

In both studies, patients received either meningococcal polysaccharide serogroup A or placebo. The 6- and 12-valent vaccines achieved a protective efficacy of 76% and 92%, respectively ...

ICMR seeks collaboration for typhoid vaccine development, inviting EoI from eligible organizations, offering technical ...